✦ LIBER ✦

Etoposide With or Without Mannitol for the Treatment of Recurrent or Primarily Unresponsive Brain Tumors: A Children's Cancer Group Study, CCG-9881

✍ Scribed by Nathan L. Kobrinsky; Roger J. Packer; James M. Boyett; Philip Stanley; Tania Shiminski-Maher; Jeffrey C. Allen; James H. Garvin; David J. Stewart; Jonathan L. Finlay

Book ID: 110234356
Publisher: Springer US
Year: 1999
Tongue: English
Weight: 62 KB
Volume: 45
Category: Article
ISSN: 0167-594X
DOI: 10.1023/a:1006333811437

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase I study of granulocyte-macrophag

A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors : A report of the Children's Cancer Group

✍ Mitchell S. Cairo; Mark D. Krailo; Joel A. Weinthal; Rita Secola; Sharon Bergero 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 3 views

## Background: This phase i trial was developed to determine the safety, biologic activity, and effects on hematopoietic recovery of pixy321 following ifosfamide, carboplatin, and etoposide chemotherapy for children with recurrent or refractory solid tumors. ## Methods: Children (age < 22 years a

A dose-intensive, cyclophosphamide-based

A dose-intensive, cyclophosphamide-based regimen for the treatment of recurrent/Progressive or advanced solid tumors of childhood : A report from the Australia and New Zealand Children's Cancer Study Group

✍ Paul A. Carpenter; Les White; Geoffrey B. McCowage; Vimala Nayanar; Ian Toogood; 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 3 views

promising salvage regimen. Continued accrual of patients and increased duration of follow-up has resulted in substantial experience with VETOPEC.